Press release
Fabry Disease Drugs Market Size 2032 | Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, and others
Fabry Disease Market
Key Takeaways from the Fabry Disease Market Research Report
• The total Fabry Disease market size in the 7MM is approximately USD 1,306 million in 2022 and is projected to increase during the forecast period (2023-2032)
• Among EU countries, the UK and Italy account for the maximum market size of USD 158, and USD 150 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 44 million.
• Japan accounts for a market size of USD 125 million in 2022, but these dynamics are expected to change in the forecast period.
• There were 15,200+ diagnosed prevalent cases of Fabry Disease estimated to have occurred in the 7MM in 2022 of which 8,300+ of the accounted cases were estimated to be from the US alone and these cases are anticipated to increase during the forecast period.
• The diagnosed prevalent cases of Fabry Disease were further divided into Phenotype-specific cases. The Phenotype-specific diagnosed prevalent cases of Fabry Disease are categorized into Classic and Late-onset with 6,900+, and 8,300+ cases respectively in the 7MM in 2022 which will further increase in 2032.
• The leading Fabry Disease Companies such as Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech, GmBH, and others.
• Promising Fabry Disease Therapies such as AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine, 4D-310, AMT-191, AL01211, Pegunigalsidase Alfa, and others.
Discover which therapies are expected to grab the major Fabry disease market share @ Fabry Disease Market Size Report- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fabry Disease Overview
Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body. Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.
Fabry Disease Epidemiology Segmentation
• Prevalent Cases of Fabry Disease
• Age-specific Cases of Fabry Disease
• Gender-specific Cases of Fabry Disease
• Diagnosed Cases of Fabry Disease
• Phenotype-specific cases
• Treated Cases
Download the report to understand which factors are driving Fabry disease epidemiology trends @ Fabry Disease Epidemiological Insights- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fabry Disease Treatment Market
Fabry disease treatment includes enzyme replacement therapy (ERT), oral chaperone therapy, and adjunctive treatment such as ACE inhibitors or angiotensin receptor blockers, antiplatelet drugs, and analgesics. Studies have shown ERT to delay, but not always prevent, some clinical complications of FD. Currently, effective Fabry disease management necessitates a multidisciplinary approach that includes intravenous ERT or chaperone therapy, as well as adjunct therapies such as lifestyle modifications and prophylactic medications.
Fabry Disease Pipeline Therapies and Key Companies
• PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
• Venglustat: Sanofi Genzyme
• ST-920: Sangamo Therapeutics
• FLT190: Freeline Therapeutics
• 4D-310: 4D Molecular Therapeutics
• Lucerastat: Idorsia Pharmaceuticals
• Moss-aGal: GREENOVATION BIOTECH GMBH
To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fabry Disease Market Dynamics
To counter the current unmet needs of the Fabry disease market and to provide better treatment options, several companies are working aggressively to develop new therapies with novel mechanisms of action. In addition, many therapies are being studied in various stages of clinical trials. Pegylated forms of -GAL, gene therapy, and substrate reduction therapy are examples of these.
Learn more about the FDA-approved drugs for Fabry disease treatment @ Drugs for Fabry Disease Treatment- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Fabry Disease Market Report
• Therapeutic Assessment: Fabry Disease's current marketed and emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Fabry Disease Market Access and Reimbursement
Discover more about drugs for Fabry disease in development @ Fabry Disease Clinical Trials- https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Fabry Disease Market Report Introduction
3. Fabry Disease Market Overview At A Glance
4. Fabry Disease Epidemiology And Market Forecast Methodology
5. Key Events
6. Executive Summary Of Fabry Disease
7. Fabry Disease Market Disease Background And Overview
8. Fabry Disease Epidemiology And Patient Population
9. Fabry Disease Patient Journey
10. Fabry Disease Marketed Drugs
11. Fabry Disease Emerging Drugs
12. Fabry Disease: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Fabry Disease Swot Analysis
15. Fabry Disease Unmet Needs
16. Fabry Disease Market Access And Reimbursement
17. Appendix
18. Delveinsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Drugs Market Size 2032 | Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, and others here
News-ID: 3604572 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
